NCT07089199
- Conditions
- Anlotinib, NSCLC, Nab-paclitaxel, +1 more
- Locations
-
- Qilu Hospital of Shandong University Jinan, Shandong, China
Clinical trial condition
Anlotinib
Explore clinical trials studying Anlotinib. Study availability and eligibility vary by location and protocol.
13 public trials
3 recruiting studies
Anlotinib trial results
NCT05167994
- Conditions
- Anlotinib, Extremity, Intensity-modulated Radiotherapy, +7 more
- Locations
-
- Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences Beijing, Beijing Municipality, China
NCT04278222
- Conditions
- Anlotinib, Digestive System Diseases, Digestive System Neoplasms, +9 more
- Locations
-
- Department of Medical Oncology, Shanghai Changzheng Hospital Shanghai, China
Not Yet Recruiting
Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
NCT07537777
- Conditions
- Adenocarcinoma, Anlotinib, Benmelstobart, +14 more
- Locations
-
- Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China
Not Yet Recruiting
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC
NCT06699498
- Conditions
- Anlotinib, Carcinoma, Carcinoma, Squamous Cell, +9 more
- Locations
-
- The First Affiliated Hospital of Nanjing Medical University Nanjing, Jiangsu, China
NCT06048315
- Conditions
- Anlotinib, EGFR Sensitive Mutation, Lung Cancer, +9 more
- Locations
-
Not specified
Not Yet Recruiting
Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation
NCT05778149
- Conditions
- Anlotinib, Aumolertinib, EGFR Activating Mutation, +2 more
- Locations
-
Not specified
NCT04271813
- Conditions
- Anlotinib, Chemo-free Therapy, Colonic Diseases, +14 more
- Locations
-
- Department of Medical Oncology, Shanghai Changzheng Hospital Shanghai, China
NCT04012619
- Conditions
- Anlotinib, Non-squamous Non-small-cell Lung Cancer
- Locations
-
- West China Hospital, Sichuan University Chengdu, Sichuan, China
NCT03936452
- Conditions
- Anlotinib, Early Stage, Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, +5 more
- Locations
-
- Sun Yat-Sen University Cancer Center Guangzhou, Guangdong, China